BridgeMD
RECURrence of Atrial Fibrillation after cardioversion of patients randomized to open-label treatment with dapagliflozin or usual care (RECUR-AF)
EU CTIS ID: 2024-513719-28-00
What this study is testing
The main objective is to evaluate whether treatment with dapagliflozin, compared to usual care, prolongs the time to atrial fibrillation recurrence within 30 days after cardioversion.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients with AF on ECG who are planned for electrical cardioversion within 7-26 from inclusion-date.
- Age ≥ 55 years.
- The subject has given their written consent to participate in the trial.
You likely can't join if
- Current treatment with SGLT2 inhibitor (dapagliflozin, empagliflozin, canagliflozin, sotagliflozin).
- Prior/current diagnosis of heart failure.
- Type 1 diabetes mellitus.
- Estimated glomerular filtration rate (eGFR) < 25 ml/min/1.73m2.
- Pulmonary vein isolation within last 3 months or planned pulmonary vein isolation within study period (56 days).
- Contraindications to SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin, sotagliflozin).
See the full eligibility criteria
- Patients with AF on ECG who are planned for electrical cardioversion within 7-26 from inclusion-date.
- Age ≥ 55 years.
- The subject has given their written consent to participate in the trial.
- Current treatment with SGLT2 inhibitor (dapagliflozin, empagliflozin, canagliflozin, sotagliflozin).
- Prior/current diagnosis of heart failure.
- Type 1 diabetes mellitus.
- Estimated glomerular filtration rate (eGFR) < 25 ml/min/1.73m2.
- Pulmonary vein isolation within last 3 months or planned pulmonary vein isolation within study period (56 days).
- Contraindications to SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin, sotagliflozin).
- Any condition or circumstance in which the patient should not participate in the study according to the study investigator.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.